enGene Therapeutics ENGN
NASDAQ ENGN
$1.78 +0.01 (+0.56%)
At close: Aug 21, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Long-Term Debt Issuances (2023 - 2026)

enGene Therapeutics (ENGN) posted quarterly Long-Term Debt Issuances of $25.0 million for Q1 2026, up 11.11% quarter-over-quarter from $22.5 million in Q1 2024.

enGene Therapeutics (ENGN) Long-Term Debt Issuances (2023 - 2026) Analysis & Trends

enGene Therapeutics (ENGN) has reported Long-Term Debt Issuances for 3 consecutive years, with $25.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $25.0 million; the TTM figure through Apr 2026 stood at $25.0 million (changed N/A YoY), while the FY2024 annual figure was $22.5 million, down 40.79% from the prior year.
  • Long-Term Debt Issuances rose to $25.0 million in Q1 2026 per ENGN's latest filing, from $22.5 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $30.0 million in Q3 2023 and bottomed at $22.5 million in Q1 2024.
  • Historically, Long-Term Debt Issuances has averaged $25.8 million across 3 years, with a median of $25.0 million in 2026.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 enGene Therapeutics 124.11 Mn 124.11 Mn - -

Historic Data

Download Data
DateValue
Jan 31, 2026 25.00 Mn
Jan 31, 2026 25.00 Mn
Jan 31, 2024 22.50 Mn
Jan 31, 2024 22.50 Mn
Jul 31, 2023 30.00 Mn
Jul 31, 2023 30.00 Mn